To evaluate the expression and clinicopathological significance of a disintegrin and metalloproteinases 19 (ADAM19) CUE domain containing protein 2 (CUEDC2) in extrahepatic cholangiocarcinoma (EHCC). Immunostaining of ADAM19 and CUEDC2 was performed by EnVision immunohistochemistry in benign and malignant biliary tract tissues. The expression of ADAM19 and CUEDC2 were significantly higher in EHCC (p < 0.05). ADAM19 expression was positive correlated with CUEDC2 expression in EHCC (p < 0.05). The overall survival time of those with positive expression of ADAM19 and CUEDC2 was lower (p < 0.001). Both positive expression of ADAM19 and CUEDC2 were independent prognostic factors in EHCC. ADAM19 and CUEDC2 have a positive correlation to the pathogenesis and dismal prognosis in EHCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/bmm-2020-0321 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of ADAM19 and CUEDC2 expression in EHCC and their clinicopathological significance.
Biomark Med
November 2020
Department of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, PR China.
To evaluate the expression and clinicopathological significance of a disintegrin and metalloproteinases 19 (ADAM19) CUE domain containing protein 2 (CUEDC2) in extrahepatic cholangiocarcinoma (EHCC). Immunostaining of ADAM19 and CUEDC2 was performed by EnVision immunohistochemistry in benign and malignant biliary tract tissues. The expression of ADAM19 and CUEDC2 were significantly higher in EHCC (p < 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!